Home LiteratureArticle Details
PMID: 24200082 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Role of inflammation-associated microenvironment in tumorigenesis and metastasis.

Current cancer drug targets ·Vol. 14 ·No. 1 ·2014-00-00 ·Pages 30-45

Gao F, Liang B, Reddy ST, Farias-Eisner R, Su X

Abstract

The tumor microenvironment contributes to every aspect of carcinogenesis and therefore offers promising targets for cancer therapy. Compared to chemotherapy alone, targeting tumor cells as well as key components of the tumor microenvironment significantly improve the clinical outcomes of patients. A better understanding of the interaction between tumor cells and the microenvironment could provide new therapeutic options and accelerate the development of novel anti-cancer drugs. In this review, we first defined the tumor microenvironment and then discussed the role of the tumor microenvironment in the initiation and progression of cancer focusing on three major pathways in a tumor cell life cycle: 1) growth and intravasation; in this section, the epithelial-mesenchymal transition (EMT), tumor cell migration, and tumor angiogenesis are reviewed. 2) dissemination; the activation and aggregation of platelets, as an important feature for the survival of tumor cells in the circulation, are reviewed under this section. 3) arrest, extravasation and growth at the secondary sites; the main contents of this section include tissue tropism in metastasis, the formation of the pre-metastatic niche, tumor cell adhesion and extravasation, the mesenchymal to epithelial transition (MET), and the formation of micrometastases and macrometastases. Finally, we briefly introduce the drug resistance mediated by the tumor microenvironment, and also summarize potential drug targets based on the current knowledge of the tumor microenvironment. Although the tumor microenvironment is equally important in the progression of carcinomas, leukemias, and sarcomas, in this review we focus on the common form of malignancy, carcinomas, which represent the malignancy derived from the epithelia.

MeSH Terms
Blood Platelets/pathology Carcinoma/drug therapy,pathology Cell Cycle Cell Movement Drug Resistance, Neoplasm Epithelial-Mesenchymal Transition Humans Inflammation/pathology Molecular Targeted Therapy Neoplasms/drug therapy,pathology Neovascularization, Pathologic Tumor Microenvironment
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Gao Feng
Liang Bin
Reddy Srinivasa T
Farias-Eisner Robin
Su Xiulan
Clinical Medicine Research Center of Affiliated Hospital, Inner Mongolia Medical University, No.1 Tongdao North Street, 010050, Hohhot, Inner Mongolia, China. xlsu@hotmail.com.
Article Info
Journal
Current cancer drug targets
Abbr.
Curr Cancer Drug Targets
ISSN
1873-5576
Published
2014-00-00
Pages
30-45
Language
English
Region
Netherlands
NLM ID
101094211
Subset
IM
Grants
NHLBI NIH HHS · HL-082823 · United States
NHLBI NIH HHS · HL-71776 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com